Novartis Ag

Kalypsys, Inc.

Other

Glaxosmithkline Biologicals Sa

Irm LLC

Timothy Z Hoffman

Tom Yao-Hsiang Wu

Alex Cortez

Yongkai Li

Xiaoyue Zhang

Yefen Zou

Jianfeng Pan

Manmohan Singh

James W Malecha

Stewart Alwyn Noble

Christian Andreus Hassig

Paul L Wash

Brandon M Wiley

Kathy Yue

Charles Maxwell Lawrence

Jun Liu

Tetsuo Uno

Xing Wang

Shailaja Kasibhatla

Bernhard Hubert Geierstanger

Dirk Behnke

Juergen Klaus Maibaum

Qihui Jin

Yun Feng Xie

Xueshi Hao

Cameron Lee

Arnaud Lacoste

Tingting Mo

Shanshan Yan

David A G Skibinski

David A G Skibinksi

Frada Berenshteyn

Yahu Liu

Xin Qu

Jan Tchorz

David Ag Skibinski

The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.

6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors

Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

Antibody conjugates comprising toll-like receptor agonist

The invention provides compounds of Formula (I), immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity. 

Compounds and compositions as toll-like receptor 7 agonists

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Adsorption of immunopotentiators to insoluble metal salts

The invention provides a compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat diseases or disorders associated with Toll-Like Receptor 7 activity.

The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.

Compounds and compositions as TLR2 agonists

The invention provides a novel class of compounds viz. generally lipopeptides like Pam3CSK4, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness a vaccine.

Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc

Disclosed herein are carbonyl compounds of Formula I as described herein.  Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease

Disclosed herein are carbonyl compounds of having the structural formula:  Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

Sulfonamides as inhibitors of histone deacetylase for the treatment of disease

Growing community of inventors

San Diego, CA, United States of America

Timothy Z Hoffman